Welcome to our dedicated page for Envista Holdings Corporation news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings Corporation stock.
Envista Holdings Corporation (NYSE: NVST) is a leading global dental products company committed to empowering dental professionals worldwide. Headquartered in Brea, California, Envista develops, manufactures, and markets an extensive portfolio of dental consumables, equipment, and services. The company operates through two primary segments: Specialty Products & Technologies and Equipment & Consumables.
The Specialty Products & Technologies segment focuses on dental implant systems, regenerative solutions, dental prosthetics, orthodontic systems, and lab products. This segment is dedicated to advancing the capabilities of dental professionals through innovative products and technologies.
The Equipment & Consumables segment offers a broad range of dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization and magnification systems, supporting the diagnostic, treatment, and prevention needs of dental conditions.
Envista has a strong commitment to continuous improvement, action-oriented innovation, and a deep respect for dental professionals. Its comprehensive product portfolio covers an estimated 90% of dentists’ clinical needs, ensuring a holistic approach to dental care.
Recent achievements include the launch of the DEXIS digital ecosystem, an AI-powered platform designed to streamline implant dentistry workflows. This interconnected system combines cutting-edge CBCT, intraoral scanning, diagnostics, and treatment planning, empowering clinicians to manage implant cases efficiently.
Envista continues to innovate with products like the ORTHOPANTOMOGRAPH™ OP 3D™ LX, which enhances 3D diagnostic capabilities, and the IS ScanFlow software, which integrates AI-driven tools to maximize productivity in dental practices.
Financially, Envista reported sales of $623.6 million for the first quarter of 2024, with core sales growth and ongoing investments aimed at accelerating growth and profitability. The company has a proven track record of resilience and strategic differentiation, particularly through the challenges posed by the global pandemic and other economic factors.
Envista's philanthropic arm, the Envista Smile Project, exemplifies its commitment to social responsibility. The project has donated millions to improve access to oral health for underserved communities, partnering with institutions like the University of Southern California to enhance dental care for vulnerable populations.
Envista's significant market positions in attractive dental segments, coupled with its continuous improvement culture and innovation-driven approach, make it a pivotal player in the dental industry. For more information, visit the official website at www.envistaco.com.
Envista Holdings Corporation (NYSE: NVST) reported a strong fourth quarter and full year 2021, following the divestiture of its KaVo Treatment Unit. Sales increased 5.8% to $651.8 million, with a core sales growth of 6.6% year-over-year. Full year core sales growth reached 29%. Fourth quarter net income was $42.5 million, with adjusted net income at $81.1 million, a 12% increase from the prior year. Looking ahead, Envista expects 2022 core growth of 6-8% and an adjusted EBITDA margin exceeding 20%, while indicating future guidance will be updated after the anticipated acquisition of Carestream Dental's IOS business.
Envista Holdings Corporation (NYSE: NVST) has renewed its partnership with the Vitaldent Group, a prominent Spanish Dental Service Organization. This agreement positions Envista as the preferred supplier for dental implants (Nobel Biocare) and clear aligners (Spark) for the next three years. Vitaldent, which has collaborated with Nobel Biocare since 2009, emphasizes the importance of innovative technology in providing quality dental care. The partnership aims to enhance clinical outcomes and patient satisfaction using advanced dental treatments.
Envista Holdings Corporation (NYSE: NVST) recently announced a five-year extension and expansion of its commercial relationship with Pacific Dental Services (PDS). This partnership will now include Envista's Spark clear aligners in addition to existing implant and imaging services. The collaboration aims to enhance implant treatment capabilities and improve diagnostic accuracy through advanced 3D imaging technology. Envista's SVP highlighted the commitment to clinical excellence, while PDS’s COO praised the partnership for enhancing patient care across over 850 supported practices.
Envista Holdings Corporation (NYSE: NVST) will report its fourth quarter 2021 financial results on February 9, 2022. A conference call to discuss these results will follow at 2:00 PM PT. Interested parties can access the call via phone or through a webcast on the company's website. A replay will be available post-presentation. Envista is a leading global dental products company, recognized for its extensive portfolio catering to 90% of dentists' clinical needs. The company focuses on continuous improvement and innovation in dental solutions.
Envista Holdings Corporation (NYSE: NVST) has announced a multi-year partnership with Pacific Dental Services (PDS) to enhance clinical image analysis through Assisted Intelligence (AI). This collaboration will utilize Envista's DTX Studio Clinic software across PDS-supported practices, enabling improved image sorting and interpretation. Both companies aim to revolutionize dental diagnostics by integrating AI and machine learning. Envista CEO Amir Aghdaei emphasized PDS as a true partner in innovation. The initiative seeks to enhance diagnosis, treatment planning, and ultimately health outcomes in dentistry.
Envista Holdings Corporation (NYSE: NVST) has successfully completed the sale of its KaVo Treatment Unit & Instrument business, receiving $317.3 million in cash upon closing. The total gross proceeds from the divestiture are projected to reach $383 million, which includes earnouts to be received by mid-2022. This strategic move allows Envista to allocate funds towards acquisitions and internal investments, enhancing its offerings to dental professionals. The Imaging business under the KaVo brand will remain with Envista.
Envista Holdings Corporation (NYSE: NVST) announced FDA clearance for its Nobel Biocare N1™ implant system, enhancing patient-centric solutions. This system integrates innovative features like the OsseoShaper™, which optimizes site preparation, improves patient comfort, and reduces noise compared to traditional methods. The N1™ also includes advanced surface treatments and is compatible with digital workflows via DTX Studio™. CEO Amir Aghdaei highlighted the growing demand for high-quality solutions in implantology. This development positions Envista to set new standards in dental implant treatment.
Envista Holdings Corporation (NYSE: NVST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2022, at 12:00 PM PST. The presentation will be virtual, and investors can access recordings on Envista's Investor Relations website under Events and Presentations. Envista is a prominent global dental products company, offering a comprehensive range of solutions to cater to dental professionals’ needs, which includes brands like Nobel Biocare and KaVo.
Envista Holdings Corporation (NYSE: NVST) announced a definitive agreement to acquire Carestream Dental's Intra-Oral Scanner business for $600 million, expected to close in Q2 2022. This acquisition aligns with Envista's strategy to capture high-growth segments in the dental market, featuring anticipated annual sales of $60 million in 2021. The acquisition is set to enhance Envista's offerings in digital dental workflows, leveraging world-class intra-oral scanners critical for procedures like implants and prosthetics. The transaction is subject to regulatory approvals.
Envista Holdings Corporation (NYSE: NVST) announced its participation in several upcoming investor conferences. Key events include the Stifel MedTech Madness on December 15, 2021, the Goldman Sachs Healthcare CEOs Unscripted Conference on January 6, 2022, and the J.P. Morgan Healthcare Conference on January 10, 2022. Investors can access recordings of these presentations on Envista's Investor Relations website. As a leading global dental products company, Envista operates over 30 trusted dental brands and aims to enhance patient care through innovative solutions.
FAQ
What is the current stock price of Envista Holdings Corporation (NVST)?
What is the market cap of Envista Holdings Corporation (NVST)?
What does Envista Holdings Corporation do?
What are the main segments of Envista's business?
What recent achievements has Envista made?
How did Envista perform financially in the first quarter of 2024?
What is the Envista Smile Project?
Who is the new CEO of Envista Holdings Corporation?
How does Envista support dental professionals?
What is the DEXIS digital ecosystem?
What is the Envista Business System (EBS)?
Where can I find more information about Envista Holdings Corporation?
